HIV-1 nef responsiveness is determined by env variable regions involved in trimer association and correlates with neutralization sensitivity

Cell Reports

Volumn 5, Issue 3, 2013, Pages 802-812

  Usami, Yoshiko ^a   Göttlinger, Heinrich ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; NEF PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN VARIABLE REGION; MOLONEY LEUKEMIA ONCOVIRUS; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SENSITIVITY ANALYSIS; VIRION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; ALLELE; AMINO ACID SEQUENCE; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HIV INFECTIONS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINE LEUKEMIA VIRUS;

ALLELES; AMINO ACID SEQUENCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEK293 CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSFECTION;

EID: 84887610878     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.09.028     Document Type: Article

References (72)

1. Abraham L., Fackler O.T. HIV-1 Nef: a multifaceted modulator of Tcell receptor signaling. Cell Commun. Signal. 2012, 10:39.
2. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J.Virol. 1997, 71:5871-5877.
3. Aiken C., Trono D. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J.Virol. 1995, 69:5048-5056.
4. Aiken C., Konner J., Landau N.R., Lenburg M.E., Trono D. Nefinduces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 1994, 76:853-864.
5. Arthos J., Cicala C., Martinelli E., Macleod K., Van Ryk D., Wei D., Xiao Z., Veenstra T.D., Conrad T.P., Lempicki R.A., et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral Tcells. Nat. Immunol. 2008, 9:301-309.
6. Baur A.S., Sawai E.T., Dazin P., Fantl W.J., Cheng-Mayer C., Peterlin B.M. HIV-1 Nef leads to inhibition or activation of Tcells depending on its intracellular localization. Immunity 1994, 1:373-384.
7. Campbell E.M., Nunez R., Hope T.J. Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. J.Virol. 2004, 78:5745-5755.
8. Cao J., Sullivan N., Desjardin E., Parolin C., Robinson J., Wyatt R., Sodroski J. Replication and neutralization of human immunodeficiencyvirus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J.Virol. 1997, 71:9808-9812.
9. Cavrois M., Neidleman J., Yonemoto W., Fenard D., Greene W.C. HIV-1 virion fusion assay: uncoating not required and no effect of Nefon fusion. Virology 2004, 328:36-44.
10. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., Wu L., Mackay C.R., LaRosa G., Newman W., et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148.
11. Chowers M.Y., Spina C.A., Kwoh T.J., Fitch N.J., Richman D.D., Guatelli J.C. Optimal infectivity invitro of human immunodeficiency virus type 1 requires an intact nef gene. J.Virol. 1994, 68:2906-2914.
12. Chowers M.Y., Pandori M.W., Spina C.A., Richman D.D., Guatelli J.C. The growth advantage conferred by HIV-1 nef is determined at the levelof viral DNA formation and is independent of CD4 downregulation. Virology 1995, 212:451-457.
13. Cohen G.B., Gandhi R.T., Davis D.M., Mandelboim O., Chen B.K., Strominger J.L., Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999, 10:661-671.
14. Collins K.L., Chen B.K., Kalams S.A., Walker B.D., Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic Tlymphocytes. Nature 1998, 391:397-401.
15. Day J.R., Münk C., Guatelli J.C. The membrane-proximal tyrosine-based sorting signal of human immunodeficiency virus type 1 gp41 is required for optimal viral infectivity. J.Virol. 2004, 78:1069-1079.
16. Deacon N.J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D.J., McPhee D.A., Greenway A.L., Ellett A., Chatfield C., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991.
17. Dorfman T., Popova E., Pizzato M., Göttlinger H.G. Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix. J.Virol. 2002, 76:6857-6862.
18. Du Z., Lang S.M., Sasseville V.G., Lackner A.A., Ilyinskii P.O., Daniel M.D., Jung J.U., Desrosiers R.C. Identification of a nef allele that causeslymphocyte activation and acute disease in macaque monkeys. Cell 1995, 82:665-674.
19. Forshey B.M., Aiken C. Disassembly of human immunodeficiency virus type 1 cores invitro reveals association of Nef with the subviral ribonucleoprotein complex. J.Virol. 2003, 77:4409-4414.
20. Garcia J.V., Miller A.D. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991, 350:508-511.
21. Goldsmith M.A., Warmerdam M.T., Atchison R.E., Miller M.D., Greene W.C. Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J.Virol. 1995, 69:4112-4121.
22. Haim H., Strack B., Kassa A., Madani N., Wang L., Courter J.R., Princiotto A., McGee K., Pacheco B., Seaman M.S., et al. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog. 2011, 7:e1002101.
23. Hu G., Liu J., Taylor K.A., Roux K.H. Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J.Virol. 2011, 85:2741-2750.
24. Jia B., Serra-Moreno R., Neidermyer W., Rahmberg A., Mackey J., Fofana I.B., Johnson W.E., Westmoreland S., Evans D.T. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 2009, 5:e1000429.
25. Johnson W.E., Morgan J., Reitter J., Puffer B.A., Czajak S., Doms R.W., Desrosiers R.C. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J.Virol. 2002, 76:2075-2086.
26. Kassa A., Finzi A., Pancera M., Courter J.R., Smith A.B., Sodroski J. Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation. J.Virol. 2009, 83:4476-4488.
27. Kestler H.W., Ringler D.J., Mori K., Panicali D.L., Sehgal P.K., Daniel M.D., Desrosiers R.C. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65:651-662.
28. Kirchhoff F., Greenough T.C., Brettler D.B., Sullivan J.L., Desrosiers R.C. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N.Engl. J. Med. 1995, 332:228-232.
29. Kolchinsky P., Kiprilov E., Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J.Virol. 2001, 75:2041-2050.
30. Krachmarov C.P., Honnen W.J., Kayman S.C., Gorny M.K., Zolla-Pazner S., Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J.Virol. 2006, 80:7127-7135.
31. Kwon Y.D., Finzi A., Wu X., Dogo-Isonagie C., Lee L.K., Moore L.R., Schmidt S.D., Stuckey J., Yang Y., Zhou T., et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. USA 2012, 109:5663-5668.
32. Laguette N., Benichou S., Basmaciogullari S. Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity. J.Virol. 2009, 83:1093-1104.
33. Lai R.P., Yan J., Heeney J., McClure M.O., Göttlinger H., Luban J., Pizzato M. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. PLoS Pathog. 2011, 7:e1002442.
34. Lama J., Mangasarian A., Trono D. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr. Biol. 1999, 9:622-631.
35. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
36. Luo T., Garcia J.V. The association of Nef with a cellular serine/threonine kinase and its enhancement of infectivity are viral isolate dependent. J.Virol. 1996, 70:6493-6496.
37. Luo T., Douglas J.L., Livingston R.L., Garcia J.V. Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. Virology 1998, 241:224-233.
38. Madrid R., Janvier K., Hitchin D., Day J., Coleman S., Noviello C., Bouchet J., Benmerah A., Guatelli J., Benichou S. Nef-induced alteration of the early/recycling endosomal compartment correlates with enhancement of HIV-1 infectivity. J.Biol. Chem. 2005, 280:5032-5044.
39. Mao Y., Wang L., Gu C., Herschhorn A., Xiang S.H., Haim H., Yang X., Sodroski J. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat. Struct. Mol. Biol. 2012, 19:893-899.
40. Mariani R., Skowronski J. CD4 down-regulation by nef alleles isolated from human immunodeficiency virus type 1-infected individuals. Proc. Natl. Acad. Sci. USA 1993, 90:5549-5553.
41. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., Clements M.L., Dolin R., Graham B.S., Gorse G.J., et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J.Infect. Dis. 1996, 173:340-348. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
42. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
43. Medjahed H., Pacheco B., Désormeaux A., Sodroski J., Finzi A. The HIV-1 gp120 major variable regions modulate cold inactivation. J.Virol. 2013, 87:4103-4111.
44. Michael N.L., Nelson J.A., KewalRamani V.N., Chang G., O'Brien S.J., Mascola J.R., Volsky B., Louder M., White G.C., Littman D.R., et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J.Virol. 1998, 72:6040-6047.
45. Miller M.D., Warmerdam M.T., Page K.A., Feinberg M.B., Greene W.C. Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J.Virol. 1995, 69:579-584.
46. O'Rourke S.M., Schweighardt B., Phung P., Fonseca D.P., Terry K., Wrin T., Sinangil F., Berman P.W. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J.Virol. 2010, 84:11200-11209.
47. O'Rourke S.M., Schweighardt B., Phung P., Mesa K.A., Vollrath A.L., Tatsuno G.P., To B., Sinangil F., Limoli K., Wrin T., Berman P.W. Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies. J.Virol. 2012, 86:12105-12114.
48. Pandori M.W., Fitch N.J., Craig H.M., Richman D.D., Spina C.A., Guatelli J.C. Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J.Virol. 1996, 70:4283-4290.
49. Pantophlet R., Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 2006, 24:739-769.
50. Peters P.J., Bhattacharya J., Hibbitts S., Dittmar M.T., Simmons G., Bell J., Simmonds P., Clapham P.R. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J.Virol. 2004, 78:6915-6926.
51. Pillemer E.A., Kooistra D.A., Witte O.N., Weissman I.L. Monoclonal antibody to the amino-terminal L sequence of murine leukemia virus glycosylated gag polyproteins demonstrates their unusual orientation in the cell membrane. J.Virol. 1986, 57:413-421.
52. Pinter A., Honnen W.J., He Y., Gorny M.K., Zolla-Pazner S., Kayman S.C. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J.Virol. 2004, 78:5205-5215.
53. Pizzato M. MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. Proc. Natl. Acad. Sci. USA 2010, 107:9364-9369.
54. Pizzato M., Helander A., Popova E., Calistri A., Zamborlini A., Palù G., Göttlinger H.G. Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc. Natl. Acad. Sci. USA 2007, 104:6812-6817.
55. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett N., Jungbauer A., et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 1994, 10:1651-1658.
56. Reil H., Bukovsky A.A., Gelderblom H.R., Göttlinger H.G. Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J. 1998, 17:2699-2708.
57. Saunders C.J., McCaffrey R.A., Zharkikh I., Kraft Z., Malenbaum S.E., Burke B., Cheng-Mayer C., Stamatatos L. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J.Virol. 2005, 79:9069-9080.
58. Schaeffer E., Geleziunas R., Greene W.C. Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J.Virol. 2001, 75:2993-3000.
59. Schiavoni I., Trapp S., Santarcangelo A.C., Piacentini V., Pugliese K., Baur A., Federico M. HIV-1 Nef enhances both membrane expression and virion incorporation of Env products. A model for the Nef-dependent increase of HIV-1 infectivity. J.Biol. Chem. 2004, 279:22996-23006.
60. Schindler M., Münch J., Kutsch O., Li H., Santiago M.L., Bibollet-Ruche F., Müller-Trutwin M.C., Novembre F.J., Peeters M., Courgnaud V., et al. Nef-mediated suppression of Tcell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006, 125:1055-1067.
61. Schwartz O., Maréchal V., Danos O., Heard J.M. Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J.Virol. 1995, 69:4053-4059.
62. Schwartz O., Maréchal V., Le Gall S., Lemonnier F., Heard J.M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 1996, 2:338-342.
63. Stamatatos L., Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J.Virol. 1998, 72:7840-7845.
64. Stanfield R.L., Gorny M.K., Williams C., Zolla-Pazner S., Wilson I.A. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 2004, 12:193-204.
65. Stolp B., Reichman-Fried M., Abraham L., Pan X., Giese S.I., Hannemann S., Goulimari P., Raz E., Grosse R., Fackler O.T. HIV-1 Nef interferes with host cell motility by deregulation of Cofilin. Cell Host Microbe 2009, 6:174-186.
66. Sullivan N., Sun Y., Binley J., Lee J., Barbas C.F., Parren P.W., Burton D.R., Sodroski J. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J.Virol. 1998, 72:6332-6338.
67. Tobiume M., Lineberger J.E., Lundquist C.A., Miller M.D., Aiken C. Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. J.Virol. 2003, 77:10645-10650.
68. Watkins J.D., Diaz-Rodriguez J., Siddappa N.B., Corti D., Ruprecht R.M. Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus. J.Virol. 2011, 85:12811-12814.
69. Welker R., Kottler H., Kalbitzer H.R., Kräusslich H.G. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 1996, 219:228-236.
70. White T.A., Bartesaghi A., Borgnia M.J., Meyerson J.R., de la Cruz M.J., Bess J.W., Nandwani R., Hoxie J.A., Lifson J.D., Milne J.L., Subramaniam S. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 2010, 6:e1001249.
71. Yang O.O., Nguyen P.T., Kalams S.A., Dorfman T., Göttlinger H.G., Stewart S., Chen I.S., Threlkeld S., Walker B.D. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic Tlymphocytes. J.Virol. 2002, 76:1626-1631.
72. Zhang F., Wilson S.J., Landford W.C., Virgen B., Gregory D., Johnson M.C., Munch J., Kirchhoff F., Bieniasz P.D., Hatziioannou T. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009, 6:54-67.